|
Mar 24
|
Evofem Reports Fourth Consecutive Year of Net Sales Growth
|
|
Mar 24
|
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
|
|
Feb 22
|
Aditxt subsidiary Persanta engages Dominary Securities for IPO
|
|
Feb 21
|
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025
|
|
Jan 13
|
Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform
|
|
Oct 21
|
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
|
|
Oct 10
|
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
|
|
Oct 9
|
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
|
|
Oct 8
|
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
|
|
Sep 4
|
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
|
|
Aug 29
|
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
|
|
Aug 26
|
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
|
|
Jul 25
|
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
|
|
Jul 25
|
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
|
|
Jul 23
|
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
|
|
May 15
|
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
|
|
May 3
|
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
|
|
Apr 2
|
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
|
|
Mar 27
|
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
|
|
Mar 7
|
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
|